Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism / Alicia GARCIA-ALCON in Journal of Autism and Developmental Disorders, 53-1 (January 2023)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 53-1 (January 2023) . - p.66-79 Titre : Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism Type de document : Texte imprimé et/ou numérique Auteurs : Alicia GARCIA-ALCON, Auteur ; Javier GONZALEZ-PENAS, Auteur ; Elisa WECKX, Auteur ; M. J. PENZOL, Auteur ; Xaquin GURRIARAN, Auteur ; Javier COSTAS, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Patricia HERNANDEZ, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur Article en page(s) : p.66-79 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Whether there is a relationship between oxytocin (OXT) use in labor and the risk of autism (ASD), and the nature of such relationship, is unclear. By integrating genetic and clinical data in a sample of 176 ASD participants, we tested the hypothesis that OXT is a marker for abnormal prenatal development which leads to impairments in the process of labor. OXT-exposed ASD had more obstetric complications (P=0.031), earlier onset of symptoms (P=0.027), poorer cognitive development (P=0.011), higher mutation burden across neurodevelopment genes (P=0.020; OR=5.33) and lower transmission of polygenic risk for ASD (P=0.0319), than non-exposed ASD. OXT seems to constitute a risk indicator rather than a risk factor for ASD, which is relevant for diagnostic and genetic counselling. En ligne : https://doi.org/10.1007/s10803-021-05409-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=492 [article] Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism [Texte imprimé et/ou numérique] / Alicia GARCIA-ALCON, Auteur ; Javier GONZALEZ-PENAS, Auteur ; Elisa WECKX, Auteur ; M. J. PENZOL, Auteur ; Xaquin GURRIARAN, Auteur ; Javier COSTAS, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Patricia HERNANDEZ, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur . - p.66-79. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 53-1 (January 2023) . - p.66-79 Index. décimale : PER Périodiques Résumé : Whether there is a relationship between oxytocin (OXT) use in labor and the risk of autism (ASD), and the nature of such relationship, is unclear. By integrating genetic and clinical data in a sample of 176 ASD participants, we tested the hypothesis that OXT is a marker for abnormal prenatal development which leads to impairments in the process of labor. OXT-exposed ASD had more obstetric complications (P=0.031), earlier onset of symptoms (P=0.027), poorer cognitive development (P=0.011), higher mutation burden across neurodevelopment genes (P=0.020; OR=5.33) and lower transmission of polygenic risk for ASD (P=0.0319), than non-exposed ASD. OXT seems to constitute a risk indicator rather than a risk factor for ASD, which is relevant for diagnostic and genetic counselling. En ligne : https://doi.org/10.1007/s10803-021-05409-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=492

Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder / Covadonga M. DIAZ-CANEJA in Journal of Child Psychology and Psychiatry, 55-9 (September 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Titre : Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder Type de document : Texte imprimé et/ou numérique Auteurs : Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur Article en page(s) : p.959-980 Langues : Anglais (eng) Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238 [article] Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder [Texte imprimé et/ou numérique] / Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur . - p.959-980. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238

Social Cognition in Autism and Schizophrenia Spectrum Disorders: The Same but Different? / L. BOADA in Journal of Autism and Developmental Disorders, 50-8 (August 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-8 (August 2020) . - p.3046-3059 Titre : Social Cognition in Autism and Schizophrenia Spectrum Disorders: The Same but Different? Type de document : Texte imprimé et/ou numérique Auteurs : L. BOADA, Auteur ; G. LAHERA, Auteur ; Laura PINA-CAMACHO, Auteur ; J. MERCHAN-NARANJO, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; J. M. BELLON, Auteur ; J. M. RUIZ-VARGAS, Auteur ; Mara PARELLADA, Auteur Article en page(s) : p.3046-3059 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders  Masc  Psychosis  Schizophrenia  Social cognition  Theory of mind Index. décimale : PER Périodiques Résumé : Social cognition impairment is a core shared phenotype in both schizophrenia spectrum disorders (SSD) and autism spectrum disorders (ASD). This study compares social cognition performance through four different instruments in a sample of 147 individuals with ASD or SSD and in healthy controls. We found that both clinical groups perform similarly to each other and worse than healthy controls in all social cognition tasks. Only performance on the Movie for the Assessment of Social Cognition (MASC) test was independent of age and intelligence. Proportionately, individuals in the control group made significantly more overmentalization errors than both patients group did and made fewer undermentalization errors than patients with SSD did. AUC analyses showed that the MASC was the instrument that best discriminated between the clinical and control groups. Multivariate analysis showed negative symptom severity as a potential mediator of the association between social cognition deficit and poor global functioning. En ligne : http://dx.doi.org/10.1007/s10803-020-04408-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=428 [article] Social Cognition in Autism and Schizophrenia Spectrum Disorders: The Same but Different? [Texte imprimé et/ou numérique] / L. BOADA, Auteur ; G. LAHERA, Auteur ; Laura PINA-CAMACHO, Auteur ; J. MERCHAN-NARANJO, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; J. M. BELLON, Auteur ; J. M. RUIZ-VARGAS, Auteur ; Mara PARELLADA, Auteur . - p.3046-3059. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-8 (August 2020) . - p.3046-3059 Mots-clés : Autism spectrum disorders  Masc  Psychosis  Schizophrenia  Social cognition  Theory of mind Index. décimale : PER Périodiques Résumé : Social cognition impairment is a core shared phenotype in both schizophrenia spectrum disorders (SSD) and autism spectrum disorders (ASD). This study compares social cognition performance through four different instruments in a sample of 147 individuals with ASD or SSD and in healthy controls. We found that both clinical groups perform similarly to each other and worse than healthy controls in all social cognition tasks. Only performance on the Movie for the Assessment of Social Cognition (MASC) test was independent of age and intelligence. Proportionately, individuals in the control group made significantly more overmentalization errors than both patients group did and made fewer undermentalization errors than patients with SSD did. AUC analyses showed that the MASC was the instrument that best discriminated between the clinical and control groups. Multivariate analysis showed negative symptom severity as a potential mediator of the association between social cognition deficit and poor global functioning. En ligne : http://dx.doi.org/10.1007/s10803-020-04408-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=428

---

1 (1 - 3 / 3)